Single-Dose Pharmacokinetics and Tolerability of Aprocitentan, a Dual Endothelin Receptor Antagonist, in Subjects with Severe Renal Function Impairment

医学 药代动力学 泌尿科 药理学 不利影响 加药 耐受性 相伴的 肾功能 内科学 置信区间 内皮素受体拮抗剂 内皮素受体 受体
作者
Patricia N. Sidharta,Ivan Ulč,Jasper Dingemanse
出处
期刊:Clinical Drug Investigation [Adis, Springer Healthcare]
卷期号:39 (11): 1117-1123 被引量:18
标识
DOI:10.1007/s40261-019-00837-x
摘要

The orally active dual endothelin receptor antagonist aprocitentan targets a novel pathway in the treatment of hypertension and could be a key player in the treatment of salt/volume-dependent hypertension. Its pharmacokinetic profile supports a once-daily dosing strategy. As hypertensive patients may also experience concomitant renal disease, the objectives of this study were to evaluate the pharmacokinetics and tolerability of aprocitentan in subjects with severe renal function impairment (SRFI) and compare these with matched healthy subjects. In this open-label, single-center, phase 1 study (NCT03165071) eight subjects with SRFI (mean estimated glomerular filtration rate [eGFR] 21.9 mL/min/1.73 m2) and eight healthy subjects (mean eGFR 94.9 mL/min/1.73 m2) received a single dose of 50 mg of aprocitentan followed by an observation period of up to 17 days. Plasma pharmacokinetic parameters of aprocitentan were derived by noncompartmental analysis of the plasma concentration-time profiles. Differences in pharmacokinetic parameters were explored using geometric means ratio (GMR) and 90% confidence intervals (CIs) with SRFI subjects as test group and healthy subjects as reference group. Safety and tolerability evaluations included adverse events (AEs), electrocardiograms, vital signs, and clinical laboratory tests. All 16 subjects received aprocitentan and completed the study. The pharmacokinetics of aprocitentan were similar in SRFI and healthy subjects with maximum plasma concentrations reached at 7.6 h and 5.0 h, respectively. Maximum plasma concentrations did not differ as indicated by a GMR (90% CI) of 1.04 (0.85–1.28). Due to a slightly lower observed clearance in SRFI subjects, half-life was longer (53.2 h compared to 47.4 h in healthy subjects), while exposure expressed as area under the curve was 34% higher (GMR 90% CI 1.13–1.58). There were no differences in plasma protein binding (> 99% bound). Aprocitentan was well tolerated in subjects with SRFI with no notable difference compared to healthy subjects. Based on these single-dose results, subjects with mild, moderate, or severe renal function can be included in clinical studies without the need for dose adjustment.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
2秒前
矮小的笑旋完成签到,获得积分10
2秒前
英姑应助Zkxxxx采纳,获得30
3秒前
9464完成签到 ,获得积分10
4秒前
4秒前
领导范儿应助贪玩的万仇采纳,获得30
6秒前
嘻嘻嘻完成签到,获得积分10
6秒前
6秒前
一点通发布了新的文献求助10
7秒前
张雷应助二艺采纳,获得20
7秒前
7秒前
李凌霄发布了新的文献求助10
9秒前
9秒前
11秒前
JamesPei应助will_fay采纳,获得10
11秒前
神勇的人雄完成签到,获得积分10
11秒前
完美世界应助woxiangbiye采纳,获得10
13秒前
Ya发布了新的文献求助10
13秒前
14秒前
余十一完成签到 ,获得积分10
15秒前
科研通AI5应助yliu采纳,获得10
16秒前
大模型应助昱珂采纳,获得10
16秒前
暴龙战士图图完成签到,获得积分10
16秒前
16秒前
魏少爷发布了新的文献求助10
17秒前
17秒前
18秒前
搜集达人应助ran采纳,获得10
20秒前
21秒前
中恐完成签到,获得积分0
22秒前
leodu完成签到,获得积分10
22秒前
李凌霄完成签到,获得积分10
23秒前
韦小宝发布了新的文献求助10
24秒前
24秒前
yep发布了新的文献求助10
24秒前
1Yer6完成签到 ,获得积分10
25秒前
kk发布了新的文献求助10
25秒前
李健的小迷弟应助yidong采纳,获得10
26秒前
zh发布了新的文献求助10
27秒前
量子星尘发布了新的文献求助10
27秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3975755
求助须知:如何正确求助?哪些是违规求助? 3520108
关于积分的说明 11200829
捐赠科研通 3256492
什么是DOI,文献DOI怎么找? 1798298
邀请新用户注册赠送积分活动 877509
科研通“疑难数据库(出版商)”最低求助积分说明 806403